UK allergy treatment developer Circassia, backed by several investors, plans on raising a total of £209m in its debut on the London Stock Exchange next week, giving it a market cap of £581m.
High-net-worth individuals and family offices are hunting for yield, concerned about low interest rates and market volatility
Fund expects to hit its target in the first quarter of 2020 and has already made six investments
Soprome and BTC Capital also back the takeover of the security services company
Perlego offers access to online textbooks for a subscription fee of £12 per month